Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders
CONCLUSION: The presented studies indicate that hyperglycemia is the initiating factor for NLRP3-induced bone disorders in diabetic patients. The main drug targets are the molecules relevant to the assembly and activation of NLRP3 inflammasome. These data may provide a theoretical basis for the further development of drugs targeting NLRP3 inflammasome in the treatment of diabetic bone disorders.PMID:36959134 | DOI:10.2174/1871530323666230320164235 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - March 24, 2023 Category: Endocrinology Authors: Yuyang Chen Munire Aili Fan Chen Yu Gong Xiaoju Chen Lan Zhang Source Type: research
Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders
CONCLUSION: The presented studies indicate that hyperglycemia is the initiating factor for NLRP3-induced bone disorders in diabetic patients. The main drug targets are the molecules relevant to the assembly and activation of NLRP3 inflammasome. These data may provide a theoretical basis for the further development of drugs targeting NLRP3 inflammasome in the treatment of diabetic bone disorders.PMID:36959134 | DOI:10.2174/1871530323666230320164235 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - March 24, 2023 Category: Drugs & Pharmacology Authors: Yuyang Chen Munire Aili Fan Chen Yu Gong Xiaoju Chen Lan Zhang Source Type: research
Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders
CONCLUSION: The presented studies indicate that hyperglycemia is the initiating factor for NLRP3-induced bone disorders in diabetic patients. The main drug targets are the molecules relevant to the assembly and activation of NLRP3 inflammasome. These data may provide a theoretical basis for the further development of drugs targeting NLRP3 inflammasome in the treatment of diabetic bone disorders.PMID:36959134 | DOI:10.2174/1871530323666230320164235 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - March 24, 2023 Category: Endocrinology Authors: Yuyang Chen Munire Aili Fan Chen Yu Gong Xiaoju Chen Lan Zhang Source Type: research
Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders
CONCLUSION: The presented studies indicate that hyperglycemia is the initiating factor for NLRP3-induced bone disorders in diabetic patients. The main drug targets are the molecules relevant to the assembly and activation of NLRP3 inflammasome. These data may provide a theoretical basis for the further development of drugs targeting NLRP3 inflammasome in the treatment of diabetic bone disorders.PMID:36959134 | DOI:10.2174/1871530323666230320164235 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - March 24, 2023 Category: Drugs & Pharmacology Authors: Yuyang Chen Munire Aili Fan Chen Yu Gong Xiaoju Chen Lan Zhang Source Type: research
Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders
CONCLUSION: The presented studies indicate that hyperglycemia is the initiating factor for NLRP3-induced bone disorders in diabetic patients. The main drug targets are the molecules relevant to the assembly and activation of NLRP3 inflammasome. These data may provide a theoretical basis for the further development of drugs targeting NLRP3 inflammasome in the treatment of diabetic bone disorders.PMID:36959134 | DOI:10.2174/1871530323666230320164235 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - March 24, 2023 Category: Endocrinology Authors: Yuyang Chen Munire Aili Fan Chen Yu Gong Xiaoju Chen Lan Zhang Source Type: research
Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders
CONCLUSION: The presented studies indicate that hyperglycemia is the initiating factor for NLRP3-induced bone disorders in diabetic patients. The main drug targets are the molecules relevant to the assembly and activation of NLRP3 inflammasome. These data may provide a theoretical basis for the further development of drugs targeting NLRP3 inflammasome in the treatment of diabetic bone disorders.PMID:36959134 | DOI:10.2174/1871530323666230320164235 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - March 24, 2023 Category: Drugs & Pharmacology Authors: Yuyang Chen Munire Aili Fan Chen Yu Gong Xiaoju Chen Lan Zhang Source Type: research
Biophysical insight into the anti-fibrillation potential of Glyburide for its possible implication in therapeutic intervention of amyloid associated diseases
Biochimie. 2023 Mar 21:S0300-9084(23)00069-X. doi: 10.1016/j.biochi.2023.03.007. Online ahead of print.ABSTRACTProtein aggregation is an underlying cause of many neurodegenerative diseases. Also, the overlapping pathological disturbances between neurodegenerative diseases and type-2 diabetes mellitus have urged the scientific community to explore potential of already available anti-diabetic medications in impeding amyloid formation too. Recent study brief out promising potential of an anti-diabetic drug Glyburide(GLY) as an inhibitor of amyloid fibrillation utilizing several biophysical techniques, computational methods an...
Source: Biochimie - March 23, 2023 Category: Biochemistry Authors: Sadia Malik Mohammad Khursheed Siddiqi Nida Naseem Faisal Nabi Aiman Masroor Nabeela Majid Amiruddin Hashmi Rizwan Hasan Khan Source Type: research
Biophysical insight into the anti-fibrillation potential of Glyburide for its possible implication in therapeutic intervention of amyloid associated diseases
Biochimie. 2023 Mar 21:S0300-9084(23)00069-X. doi: 10.1016/j.biochi.2023.03.007. Online ahead of print.ABSTRACTProtein aggregation is an underlying cause of many neurodegenerative diseases. Also, the overlapping pathological disturbances between neurodegenerative diseases and type-2 diabetes mellitus have urged the scientific community to explore potential of already available anti-diabetic medications in impeding amyloid formation too. Recent study brief out promising potential of an anti-diabetic drug Glyburide(GLY) as an inhibitor of amyloid fibrillation utilizing several biophysical techniques, computational methods an...
Source: Biochimie - March 23, 2023 Category: Biochemistry Authors: Sadia Malik Mohammad Khursheed Siddiqi Nida Naseem Faisal Nabi Aiman Masroor Nabeela Majid Amiruddin Hashmi Rizwan Hasan Khan Source Type: research
Medications for Managing Preexisting and Gestational Diabetes in Pregnancy
Persons with gestational and pregestational diabetes during pregnancy may require pharmacologic agents to achieve pregnancy glycemic targets, and the available medications for use in pregnancy are limited. Insulin is the only FDA-approved medication for use in pregnancy and has the greatest evidence for safety and efficacy. Metformin and glyburide are the most commonly used oral agents in pregnancy. Understanding each medication ’s unique pharmacokinetics, potential side effects, fetal or childhood risks, gestational age of medication initiation and patient’s diabetes care barriers are important aspects of shared decis...
Source: Obstetrics and Gynecology Clinics - February 22, 2023 Category: OBGYN Authors: Michaela Rickert, Aaron B. Caughey, Amy M. Valent Source Type: research
